Literature DB >> 17532675

Panic Attack Precipitated by Tegaserod plus Fluoxetine.

Ilker Tasci1, Murat Gulsun.   

Abstract

Entities:  

Year:  2005        PMID： 17532675     DOI： 10.2165/00044011-200525050-00010

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  25 in total

Review 1.  Antidepressant use in clinical practice: efficacy v. effectiveness.

Authors:  J Donoghue; T R Hylan
Journal:  Br J Psychiatry Suppl       Date:  2001-09

2.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

3.  Antidepressants and chronic pain.

Authors:  H J McQuay; R A Moore
Journal:  BMJ       Date:  1997-03-15

4.  Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.

Authors:  B Coffin; J-P Farmachidi; P Rueegg; A Bastie; D Bouhassira
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions.

Authors:  A E Vickers; M Zollinger; R Dannecker; R Tynes; F Heitz; V Fischer
Journal:  Drug Metab Dispos       Date:  2001-10       Impact factor: 3.922

Review 6.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 7.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

8.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

Authors:  Adrián LLerena; Pedro Dorado; Roland Berecz; Antonio P González; Eva M Peñas-LLedó
Journal:  Eur J Clin Pharmacol       Date:  2004-01-16       Impact factor: 2.953

9.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Irritable bowel syndrome in the general population.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1992-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.